The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
==== Management of future flooding ==== The floodings from earlier in the year became an issue during the course of his reelection campaign in 2024. After he was questioned about the subject, Melo mentioned that "it will continue to flood". According to him, the situation would depend on drainage systems, but the budget did not cover projects to protect against flooding, and the new investment of $4.5 billion real would depend on the creation of a partnership with the Municipal Department of Water and Sewage (DMAE). During the same time period, strong rains affected the city, leaving the city without lights and transport, also affecting the swearing in of municipal secretaries, which had to be cancelled after the rain took out the lights. Former minister of president Lula da Silva, Paulo Pimenta, criticized Melo for his stance on the issue, claiming that he was responsible for the new bouts of flooding in Porto Alegre.
Komagataella is a methylotrophic yeast within the order Pichiales. It was found in the 1960s as Pichia pastoris, with its feature of using methanol as a source of carbon and energy. In 1995, P. pastoris was reassigned into the sole representative of genus Komagataella, becoming Komagataella pastoris. In 2005, it was found that almost all strains used industrially and in labs are a separate species, K. phaffii. Later studies have further distinguished new species in this genus, resulting in a total of 7 recognized species. It is not uncommon to see the old name still in use in the context of protein production, as of 2023; in less formal use, the yeast may confusingly be referred to as pichia. After years of study, Komagataella is widely used in biochemical research and biotech industries. With strong potential for being an expression system for protein production, as well as being a model organism for genetic study, Komagataella phaffii has become important for biological research and biotech applications.
=== Sources === This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2025, Food and Agriculture Organization of the United Nations. This article incorporates text from a free content work. Licensed under CC BY-SA 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2024, Food and Agriculture Organization.
Sources: en.wikipedia.org
== Protein structure == The first structure of a creatine kinase solved by X-ray protein crystallography was that of the octameric, sarcomeric muscle-type mitochondrial CK (s-mtCK) in 1996., followed by the structure of ubiquitous mitochondrial CK (u-mtCK) in 2000. The atomic structure of the banana-shaped, dimeric cytosolic brain-type BB-CK was solved in 1999 at a resolution of 1,4 Å. Cytosolic BB-CK, as well as muscle-type MM-CK both form banana-shaped symmetric dimers, with one catalytic active site in each subunit.
During this meeting, he asked what Weizmann's objections had been to the 1903 Uganda Scheme that Herzl had supported to provide a portion of British East Africa to the Jewish people as a homeland. The scheme, which had been proposed to Herzl by Joseph Chamberlain, Colonial Secretary in Balfour's Cabinet, following his trip to East Africa earlier in the year, had been subsequently voted down following Herzl's death by the Seventh Zionist Congress in 1905 after two years of heated debate in the Zionist Organization. Weizmann responded that he believed the English are to London as the Jews are to Jerusalem. In January 1914, Weizmann first met Baron Edmond de Rothschild, a member of the French branch of the Rothschild family and a leading proponent of the Zionist movement, in relation to a project to build a Hebrew university in Jerusalem. The Baron was not part of the World Zionist Organization, but had funded the Jewish agricultural colonies of the First Aliyah and transferred them to the Jewish Colonization Association in 1899. This connection was to bear fruit later that year when the Baron's son, James de Rothschild, requested a meeting with Weizmann on 25 November 1914, to enlist him in influencing those deemed to be receptive within the British government to the Zionist agenda in Palestine. Through James's wife Dorothy, Weizmann was to meet Rózsika Rothschild, who introduced him to the English branch of the family – in particular her husband Charles and his older brother Walter, a zoologist and former Member of Parliament (MP).
The radioactive 35S is formed in cosmic ray spallation of the atmospheric 40Ar. This fact may be used to verify the presence of recent (less than a year old) atmospheric sediments in various materials. This isotope may be obtained artificially in different ways. In practice, the reaction 35Cl + n → 35S + p is used, irradiating potassium chloride with neutrons. The isotope 35S is used in various sulfur-containing compounds as a radioactive tracer for many biological studies, for example, the Hershey-Chase experiment. Because of the weak beta activity of 35S, its compounds are relatively safe as long as they are not ingested or absorbed by the body.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.